Sona’s ‘THT’ Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study
Halifax, Nova Scotia — (Newsfile Corp. – September 11, 2023) – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the “Research Group”). This study aims to evaluate the efficacy of Sona’s Targeted Hyperthermia Therapy (“THT”) technology in not only attenuating the development of colorectal, breast, and melanoma tumor models in mice but also in facilitating systemic immune responses.
The study posits that the combined utilization of Sona’s gold nanorods via its Targeted Hyperthermia Therapy, alongside precise immune modulation, will result in elevated immune activation and anti-tumor responses within the mouse models of colorectal cancer, breast cancer, and melanoma.
Sona CEO, David Regan, commented, “This innovative study will go significantly beyond our current plans for Targeted Hyperthermia Therapy applications to explore the potentially synergistic effect of its use with certain immunotherapy treatments for cancer. In it, we aim to harness the tremendous potential of immunotherapy, leveraging Sona’s biocompatible gold nanorods as a pivotal, catalytic element. This effort marks the beginning of Sona delivering on the ‘mountain of data’ we committed to developing in support of our planned regulatory submissions for human clinical trial approvals.”
